|Day Low/High||42.07 / 42.57|
|52 Wk Low/High||37.43 / 45.62|
Insulin has been around since 1921. But there is no generic drug and four companies control the market. Now politicians, the AMA and patient groups are looking for lower prices.
While a handful of drug companies say their average net prices have dropped, FDA Commissioner Scott Gottlieb announces a plan to encourage drug competition in the face of monopolies.
Senior vice president Enrique Conterno says the Type-2 diabetes treatment is part of the fast-growing glucagon-like peptide-1 receptor agonists.
The tough news keeps coming at the generic drug company, which announced last week it was considering putting itself up for sale. Now the Justice Department wants a chat.
The Philippine government says Sanofi knew that the vaccine should not have been given to people who have never had dengue fever.
The charges were related to an interest-rate problem.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: OMC, WMS Downgrades: ALSK, ATV, BP, CARB, CMP, CRL, DAN, FRT, SNY, VNO, WU, ZIXI Initiations: None Read on to get TheStreet Quant Ratings' detailed report:
The Creating and Restoring Equal Access to Equivalent Samples Act, a measure aimed at making it easier for generic drug companies to research name brand drugs, was left out of the final budget.
A steeper fall might cause both buyers and sellers to re-think potential deals, but so far that doesn't seem to be the case yet.
A week after unveiling an $11.6-billion deal for Bioverativ, Sanofi said it was spending another $4.8 billion to acquire Belgian biotech firm Ablynx.
U.S. stock futures trade lower, Donald Trump's national security advisers look at building a 5G network, and France's Sanofi buys Belgian biotech Ablynx.
As the Trump administration reportedly considers government controlled 5G, investors prepare for a hectic week of earnings.
Consumer spending should be more than solid given wage increases.
Here's what you need to know now for Monday, Jan. 22.
With a boost from the NFL and its own IPO, Quanterix hopes to engage biopharma companies to use its platform to speed safety and efficacy results for neurology, oncology and inflammation pipelines.
A flurry of high-priced merger-and-acquisition activity explains the move in Allergan.
Stocks hit fresh records on Monday after a deal is reached to end the three-day government shutdown.
Stocks turn higher on Monday, as investors watch for the impact of a federal government shutdown that entered its third day.
Another New England Patriots win in the Super Bowl could mean bad things for the stock market. What government shutdown?
The stock market's impressive start to the year is at risk as the government shutdown enters day three. Meanwhile, a series of healthcare deals captivates Wall Street's attention.
So what does a government shutdown mean for today's trading? Here's what you need to know before Monday's opening bell.
U.S. stock futures suggest Wall Street will open lower on Monday, as investors watch for the impact of a federal government shutdown that has extended into its third day.
France's Sanofi could end its long search for a biotech deal after striking an $11.6 billion offer for Massachusetts-based Bioverativ, a maker of hemophilia treatments.
Helped by a relaxed regulatory environment, telco giants could pursue M&A to build and prioritize their own content libraries.
Sanofi has launched two new late-stage clinical studies to determine if an investigational biologic called isatuximab, when used in combination with other commonly used cancer treatments, might be an effective treatment...
Some French companies will get a temporary windfall, but others will need to pay more tax.
Tesla and General Motors are among this week's names showing reversal patterns.
The French drugmaker's under pressure diabetes treatments slid less than expected but sales of its growing multiple sclerosis products underwhelmed.
Investors keep an eye on another busy slate of earnings.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.